arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MYRIAD GENETICS INC

MYGN
$6.29 ▲ +0.27 (+4.49%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

MYRIAD GENETICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $582.5M
Dividend Yield —
Revenue Growth -1.6% ↘
Op. Margin -47.0% ↘
ROIC -73.5% ↘
FCF / Share $0.02 ↗
Trailing P/E —
Price / Book 1.6x
FCF Yield 0.3%
Debt / Equity 0.33
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$824.50M
↓ -1.6% —
Net Income Profit after all expenses
$-365.90M
↓ -187.4% —
Operating Margin Operating profit as % of sales
-47.0%
↓ -218.5% 5th
FCF / Share Free cash flow per share
$0.02
↑ +120.2% —
Long-Term Debt Long-term obligations
$119.90M
↑ +202.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
12
Returns ↓
9
Financial Health ↓
40
Cash Quality ↑
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 72 quarters